Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azilect

ApprovedSmall molecule

Azilect is one of 13 small molecule programs targeting Apathy. It is currently in Approved.

1

Indications

6

Total Trials

0

Active Trials

12

Competitors

Pipeline

Status by Indication[3][1]

Indication

ApathyActive, not recruiting

ApathyApproved

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Apathy

#DrugCompanyPhaseTrials

Cialis

Azilect

Neupro

Dexedrine Spansule

Innovent Biologics (Suzhou) Co. Ltd.

Ulotaront

IIntra-Cellular Therapies, Inc.

Risperdal

Provigil

NNuvo Research GmbH

Ritalin

Wellbutrin

GGlaxo Dba Glaxosmithkline

Azilect

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease2 trials

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01268891·132 enrolled

Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline

Completed·TTechnische Universität Dresden·Phase 4·NCT00902941·34 enrolled

ALK1 trial

Ambulosono Rasagiline Musical Walking Study

Unknown status·UUniversity of British Columbia·N/A·NCT02207387·60 enrolled

Parkinson's1 trial

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

Completed· Lundbeck logo

Lundbeck·Phase 3·NCT01479530·321 enrolled

Apathy1 trial

Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study

Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 4·NCT01765257·50 enrolled

Unspecified1 trial

Azilect® In Wearing-Off (AIWO)

Completed· Teva logo

Teva··NCT02384512·261 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Azilect. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azilect compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azilect. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lundbeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Lundbeck

Related News